NERV Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 10.28%, SMA50 30.76%, SMA200 102.56%). The stock’s 14-day RSI is 67.11 (firm momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.0% below its high and over 441.74% above its low. Average 10-day trading volume of 237.39 thousand shares is in line with the 3-month average of 216.78 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$362,525.30. The next quarter is forecast at -$0.30. Next year's EPS is expected at $18.78. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $4.00. The high target offers 138.5% upside. The low target suggests -31.86% downside. The mean target is $8.33. This offers 41.91% upside. Minerva Neurosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 103578557.31%. The prior quarter beat by -54.74%. Over the last six quarters, Apple has recorded several small beats. These include 112143541.63% in August 06, 2024.

Minerva Neurosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.05. This means the shares are trading above this model’s fair value.

Minerva Neurosciences, Inc. has 43.27 million shares outstanding. The public float is 3.98 million shares, elevated short interest at 1.07% of float. This equals 432.78 thousand shares. The short ratio is 4.55 days. Institutional investors hold 36.01% of the float. Insiders own 22.25%. De Rubertis Francesco holds 4.49 million shares, Ollier Michele has 4.49 million shares and Index Venture Associates III Ltd has 3.90 million shares.

Minerva Neurosciences, Inc. (NASDAQ:NERV) closed at $6.18 USD, gaining $0.31 (5.28%) from the previous close of $5.87. The stock is currently mid-range between its 52-week high and low $1.30 and $12.46. With a market capitalization of about $43.22 million, Minerva Neurosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 242.10 thousand shares, in line with its 52-week average. Headquartered in Burlington, MA, Minerva Neurosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Remy Luthringer, the company employs approximately 8 people and listed since July 01, 2014. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

Minerva Neurosciences, Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.47 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.76, also below market averages.

Our AI price prediction model suggests that Minerva Neurosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.67%, with price expected at $5.42 by April 28, 2026, within a range of $4.44 to $6.43 3-Month Outlook: Projected rise of 24.87%, reaching $7.33 by July 13, 2026, with a range of $6.89 to $7.81. 1-Year Outlook: Projected gain of 378.71%, with price at $28.10 by April 14, 2027, within a range of $29.64 to $30.98.

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares are flat 8.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Minerva Neurosciences, Inc. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $11.13, suggesting 89.61% upside. Our AI forecast model points to short-term weakness (-7.67% over two weeks), a medium-term rise (24.87% over three months), and a longer-term gain (378.71% over one year), with expected trading ranges indicating moderate volatility.